Cytosorbents Corp Faces Delisting Concerns

TL;DR

Cytosorbents Corp might be delisted - big trouble ahead.

AI Summary

Cytosorbents Corporation filed an 8-K on October 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The earliest event reported was on October 2, 2025. The company is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This filing indicates potential issues with Cytosorbents Corporation's continued listing on an exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial stability.

Key Players & Entities

• Cytosorbents Corporation (company) — Registrant
• October 2, 2025 (date) — Earliest event reported
• October 3, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Princeton, New Jersey (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke
• $1.00 — Company's common stock had fallen below $1.00 per share for 30 consecutive business d

Filing Documents

• tm2527881d1_8k.htm (8-K) — 25KB
• 0001104659-25-096675.txt ( ) — 185KB
• ctso-20251002.xsd (EX-101.SCH) — 3KB
• ctso-20251002_lab.xml (EX-101.LAB) — 33KB
• ctso-20251002_pre.xml (EX-101.PRE) — 22KB
• tm2527881d1_8k_htm.xml (XML) — 3KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 2, 2025, CytoSorbents Corporation (the "Company") received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company's common stock had fallen below $1.00 per share for 30 consecutive business days (the "Minimum Bid Price Requirement"). The written notification has no immediate effect on the listing or trading of the Company's common stock. In accordance with applicable Nasdaq rules, the Company has 180 calendar days following the date of the written notice, or until March 31, 2026 (the "Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date, unless the Nasdaq staff exercises its discretion to require the Company to meet the Minimum Bid Price Requirement for a longer period pursuant to applicable Nasdaq rules. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company would be eligible for an additional compliance period of 180 days provided it presents an acceptable plan to NASDAQ to regain compliance. The Company intends to actively monitor the closing bid price of its common stock, and will consider its options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq listing standards.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 3, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR